Joris Pezzini joins Alira Health as Partner

Alira Health welcomes Joris Pezzini as Partner

Former head of business development at UCB will specialize in pharma and biotech innovation. 

Joris PezziniBOSTON, USA – Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, announced that Joris Pezzini has joined the firm as Partner. Joris brings a background in biotechnology and 15 years of experience leading strategy and business development in healthcare.

“Bringing Joris to Alira Health demonstrates our dedication to the innovative biotechnology and pharmaceutical industries,” says Benjamin Chambon, Alira Health’s Chief Operating Officer. “His technical knowledge and strong leadership skills complement our services, and together we will be able to provide our clients with even deeper insights and inventive solutions.”

“I’m thrilled to join Alira Health to help further develop the company’s Biotech and Pharma portfolio,” says Joris Pezzini. “I believe the firm is uniquely positioned to bring substantial value to clients through our integrated teams of strategists, bankers, doctors, and scientists. Alira Health has the ability to understand all aspects of the industry, which is critical for successful innovation.”

Joris Pezzini joined Alira Health in January 2019 and is based in Barcelona, Spain. To learn more about the Alira Health team, please visit https://www.alirahealth.com/about-us/team/.

 

About Joris Pezzini:

Joris Pezzini is a Biopharma executive with 15 years of experience in the healthcare industry, gained through science and business roles in start-up, mid-size pharma, and consulting firms.

Before joining Alira Health in 2019, Joris led business development activities for UCB, a €4B pharma company focusing on neurology, immunology, and bone diseases.

Prior to UCB, Joris served as Executive Vice President of Strategy and Business Development at LFB, a €500M, 2000 employee Biopharma firm developing immunology products through four proprietary platforms (plasma derivatives, transgenic animals, cell culture, and cell therapy).

Before LFB, Joris spent three years at Bionest Partners as a strategy consultant in healthcare. He began his career as a scientist in California and the UK specializing in the production of monoclonal antibodies.

Joris is a biotechnology engineer from ENSTBB and holds a business and leadership degree from Harvard Business School.